The Research Goes On…

Today, Dr Beljanski’s legacy continues through the work and support of the Beljanski Foundation. His research has garnered the attention of several prominent institutions in America. Mirko Beljanski’s work was not only confirmed but deepened:

• Columbia University, New York (2004-2009) :

Columbia University, New York City.

At Columbia University, Dr. Aaron Katz’s team conducted more research to confirm the efficacy of the plant extracts as identified by Mirko Beljanski, Rauwolfia vomitoria and Pao pereira (Geissospermum vellosii). Dr. Aaron Katz, MD and Debra Bemis, PhD have explored and confirmed that the Rauwolfia vomitoria and the Pao pereira contains ß-Carbolines with interesting anticancer properties.

Publications of their findings:

• “A Novel Combination of Plant Extracts with Promising Anti-Prostate Cancer Activity” by John Hall, PhD, Natacha Springer, Msc, and Debra Bemis, PhD
  Townsend Letter – December 2004
• “Anti-prostate cancer activity of B-carboline alkaloid enriched extract from Rauwolfia vomitoria” by D.L. Bemis, J.L. Capodice, P. Gorroochurn, A.E. Katz and R. Buttyan
  International Journal of Oncology 29: 1065-1073, 2006
• “B-Carboline Alkaloid-Enriched Extract from the Amazonian Rain Forest Tree Pao Pereira Suppresses Prostate Cancer Cells” by Debra L. Bemis, PhD, Jillian L. Capodice, LAc, MS, Manisha Desai, PhD, Aaron E. Katz, MD, Ralph Buttyan, PhD
  Journal of the Society for Integrative Oncology, Vol 7, No 2 (Spring), 2009

Furthermore, a clinical trial to test the synergistic effects of Rauwolfia vomitoria and Pao pereira (Pau pereira) on men with a negative biopsy and elevated PSA was recently executed at the Columbia University, Department of Holistic Urology, under the direction of Dr. Geovanni Espinosa.

• “Two Herbal Extracts for Protecting Prostate Cell DNA – IMCJ April 2010” by Melissa Burchill, RN, CDN
  IMCJ (Integrative Medicine: A clinician’s journal) – April-May 2010

• Cancer Treatment Centers of America, Chicago (2010)

The prestigious Cancer Treatment Centers of America (CTCA) have recently completed a clinical trial on the extraordinary Beljanski formula of RNA fragments, which was conducted among cancer patients undergoing different chemotherapies. Thanks to the RNA fragments prepared according to Dr Beljanski’s proprietary process, the cancer patients all recovered a stronger immune system and managed to go through the end of their chemotherapy treatment without getting thrombocytopenia – a frequent and dangerous side effect of the chemotherapy drugs.

Publication of the results:

“Dose escalation study of an antithrombacytopenic agent in patients with chemotherapy induced thrombocytopenia” by Robert D Levin, MaryAnn Daehler, James F Grutsch, John L Hall, Digant Gupta, Christopher G Lis. Levin
Online magazine Bio Med Central BMC Cancer 10:565 – 2010

• Upcoming new research projects:

A new research project is under way with Kansas University Medical Center. The research team will study the anti-cancer activity of the Pao pereira and Rauwolfia vomitoria on ovarian and pancreas cancer cells.